Experienced in Ewing Sarcoma

Olaf Witt

Heidelberg, BW, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Ewing Sarcoma
Heidelberg, BW, DE 
OverviewLocationsClinical Research

Overview

Olaf Witt practices in Heidelberg, Germany. Mr. Witt is rated as an Experienced expert by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Gliomatosis Cerebri, Glioma, Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, and Tissue Biopsy.

His clinical research consists of co-authoring 211 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Ewing Sarcoma.

Gender
Male

Locations

Heidelberg, BW, Germany
Other Locations
Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies (INFORM2-NivEnt)
INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies (INFORM2-NivEnt)
Enrollment Status: Recruiting
Publish Date: February 07, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Enrollment Status: Completed
Publish Date: October 03, 2024
Intervention Type: Drug
Study Drug: Tazemetostat
Study Phase: Phase 1
View 1 Less Clinical Trial

211 Total Publications

High 4E-BP-1 expression associates with chromosome 8 gain and CDK4/6 sensitivity in Ewing Sarcoma.
High 4E-BP-1 expression associates with chromosome 8 gain and CDK4/6 sensitivity in Ewing Sarcoma.
Journal: The Journal of clinical investigation
Published: October 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Witt's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 31 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile